Traders should watch for a prospectus supplement announcing a priced offering, which typically follows effectiveness within days to weeks for clinical-stage biotechs. Any announced offering size below ~$50M may be digestible; a larger raise could pressure the stock given the weak T+20 historical performance on recent filings. Monitor insider buying/selling patterns for signals on whether management views the current valuation as attractive ahead of potential dilution.
Price Chart
Executive Summary
Protara Therapeutics' registration statement on Form S-3 (File No. 333-295862) was declared effective on May 22, 2026. This enables the company to conduct primary and/or secondary offerings of securities at any time, creating potential dilution overhang for common stock shareholders. The effectiveness comes as the company's $277M market cap biotech carries strong analyst bullish consensus (93% buy) but with negative historical alpha at T+20.
Key Facts
- Form S-3 shelf registration became effective May 22, 2026.
- Registration covers issuance of common stock, preferred stock, warrants, debt securities, and/or units.
- No specific pricing, amount, or intended use of proceeds was disclosed in the effectiveness notice.
- Company is a clinical-stage biotech with $277M market cap and 93% analyst buy rating.
- Historical TARA filings have shown negative mean alpha at T+20 (-2.78%) in the filing_report segment.
Financial Impact
Undisclosed — no offering size or terms were provided in the effectiveness notice. Shelf registration is effective immediately, so the company can conduct offerings at any time.
Risk Factors
- Immediate risk: company may announce a dilutive offering at any time now that the shelf is effective.
- Clinical-stage biotech with no approved products — pipeline failure could compound dilution risk.
- Negative T+20 alpha on prior TARA filings suggests bearish momentum over medium-term windows.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| EFFECT Filing (Primary) | 9999999995-26-001748 |
| Document: 9999999995-26-001748-index.html | 9999999995-26-001748 |
| Document: 9999999995-26-001748.txt | 9999999995-26-001748 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 11, 2026 7w ago | 8-K | $3.91 $3.83 | ▼ −2.05% | ▼ −0.99% | $2.70 (−30.95%) |
Aug 11, 2026 7w ago | Press Release | $3.91 $3.83 | ▼ −2.05% | ▼ −0.99% | $2.70 (−30.95%) |
Jun 29, 2026 13w ago | 8-K | $3.82 $4.04 | ▲ +5.76% | ▲ +6.79% | $2.70 (−29.32%) |
May 26, 2026 18w ago | EFFECT | $4.80 $4.06 | ▲ +15.52% | ▲ +13.57% | $2.70 (+43.75%) |
May 15, 2026 20w ago | Press Release | $5.10 $3.94 | ▼ −22.75% | ▼ −24.86% | $2.70 (−47.06%) |
May 13, 2026 20w ago | 8-K | $5.20 $3.65 | ▼ −29.81% | ▼ −29.19% | $2.70 (−48.08%) |
May 13, 2026 20w ago | Press Release | $5.20 $3.65 | ▼ −29.81% | ▼ −29.19% | $2.70 (−48.08%) |
Apr 28, 2026 22w ago | DEFA14A | $5.17 $4.75 | ▼ −8.12% | ▼ −14.17% | $2.70 (−47.78%) |
Mar 10, 2026 29w ago | Press Release | $5.71 $5.22 | ▼ −8.58% | ▼ −8.43% | $2.70 (−52.71%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access